{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:16:16Z","timestamp":1790806576927,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40259-023-00590-w","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T11:24:43Z","timestamp":1680607483000},"page":"375-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-602X","authenticated-orcid":false,"given":"Valentina D.","family":"Gusarova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-7655","authenticated-orcid":false,"given":"Maxim A.","family":"Smolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9058-1106","authenticated-orcid":false,"given":"Ivan V.","family":"Lyagoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-5575","authenticated-orcid":false,"given":"Maksim B.","family":"Degterev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta V.","family":"Rechetnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Rodionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina S.","family":"Pantyushenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-7835","authenticated-orcid":false,"given":"Rahim R.","family":"Shukurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"2","key":"590_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1055\/s-0028-1109958","volume":"228","author":"K Schopfer","year":"2011","unstructured":"Schopfer K, Miebach E, Beck M, Pitz S. Lysosomal storage diseases: update and new therapeutic options. Klin Monbl Augenheilkd. 2011;228(2):144\u201360. https:\/\/doi.org\/10.1055\/s-0028-1109958.","journal-title":"Klin Monbl Augenheilkd"},{"key":"590_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1152\/physiol.00041.2009","volume":"25","author":"EJ Parkinson-Lawrence","year":"2010","unstructured":"Parkinson-Lawrence EJ, Shandala T, Prodoehl M, et al. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology. 2010;25:102\u201315. https:\/\/doi.org\/10.1152\/physiol.00041.2009.","journal-title":"Physiology"},{"key":"590_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","volume":"13","author":"RJ Desnick","year":"2012","unstructured":"Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307\u201335. https:\/\/doi.org\/10.1146\/annurev-genom-090711-163739.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"590_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.beem.2014.12.001","volume":"29","author":"M Scarpa","year":"2015","unstructured":"Scarpa M, Bellettato CM, Lampe C, Begley DJ. Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system. Best Pract Res Clin Endocrinol Metab. 2015;29:159\u201371. https:\/\/doi.org\/10.1016\/j.beem.2014.12.001.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"590_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00431-006-0316-8","volume":"166","author":"V Tokic","year":"2007","unstructured":"Tokic V, Barisic I, Huzjak N, et al. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr. 2007;166:727\u201332. https:\/\/doi.org\/10.1007\/s00431-006-0316-8.","journal-title":"Eur J Pediatr"},{"issue":"8","key":"590_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3928\/00904481-20090723-09","volume":"38","author":"ER Lim-Melia","year":"2009","unstructured":"Lim-Melia ER, Kronn DF. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009;38(8):448\u201355. https:\/\/doi.org\/10.3928\/00904481-20090723-09.","journal-title":"Pediatr Ann"},{"issue":"1","key":"590_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/iub.284","volume":"62","author":"M Beck","year":"2010","unstructured":"Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62(1):33\u201340. https:\/\/doi.org\/10.1002\/iub.284.","journal-title":"IUBMB Life"},{"key":"590_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","volume":"31","author":"S Al Sawaf","year":"2008","unstructured":"Al Sawaf S, Mayatepek E, Hoffmann B. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis. 2008;31:473\u201380. https:\/\/doi.org\/10.1007\/s10545-008-0878-x.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"590_CR9","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","volume":"124","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228\u201339. https:\/\/doi.org\/10.1542\/peds.2008-0999.","journal-title":"Pediatrics"},{"key":"590_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/jcpt.12136","volume":"39","author":"H Noh","year":"2014","unstructured":"Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39:215\u201324. https:\/\/doi.org\/10.1111\/jcpt.12136.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"590_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","volume":"31","author":"MM Patel","year":"2017","unstructured":"Patel MM, Patel BM. Crossing the blood\u2013brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109\u201333. https:\/\/doi.org\/10.1007\/s40263-016-0405-9.","journal-title":"CNS Drugs"},{"issue":"7","key":"590_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/21678707.2018.1487838","volume":"6","author":"R Giugliani","year":"2018","unstructured":"Giugliani R, Dalla Corte A, Poswar F, et al. Intrathecal\/intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects. Expert Opin Orphan Drugs. 2018;6(7):403\u201311. https:\/\/doi.org\/10.1080\/21678707.2018.1487838.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"2","key":"590_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/ijms21020400","volume":"21","author":"Y Sato","year":"2020","unstructured":"Sato Y, Okuyama T. Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses. Int J Mol Sci. 2020;21(2):400. https:\/\/doi.org\/10.3390\/ijms21020400.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"590_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1021\/bc800148t","volume":"19","author":"WM Pardridge","year":"2008","unstructured":"Pardridge WM. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem. 2008;19(7):1327\u201338. https:\/\/doi.org\/10.1021\/bc800148t.","journal-title":"Bioconjug Chem"},{"key":"590_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1021\/bc900382q","volume":"21","author":"JZ Lu","year":"2010","unstructured":"Lu JZ, Hui EK-W, Boado RJ, Pardridge WM. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug Chem. 2010;21:151\u20136. https:\/\/doi.org\/10.1021\/bc900382q.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"590_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3109\/13550289909021285","volume":"5","author":"WM Pardridge","year":"1999","unstructured":"Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol. 1999;5(6):556\u201369. https:\/\/doi.org\/10.3109\/13550289909021285.","journal-title":"J Neurovirol"},{"issue":"2","key":"590_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/17425247.2014.952627","volume":"12","author":"WM Pardridge","year":"2015","unstructured":"Pardridge WM. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015;12(2):207\u201322. https:\/\/doi.org\/10.1517\/17425247.2014.952627.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"590_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/bit.21120","volume":"96","author":"RJ Boado","year":"2007","unstructured":"Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96(2):381\u201391. https:\/\/doi.org\/10.1002\/bit.21120.","journal-title":"Biotechnol Bioeng"},{"issue":"5","key":"590_CR19","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","volume":"26","author":"H Sonoda","year":"2018","unstructured":"Sonoda H, Morimoto H, Yoden E, et al. A blood\u2013brain\u2013barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.032.","journal-title":"Mol Ther"},{"issue":"5","key":"590_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.ymthe.2021.01.027","volume":"29","author":"H Morimoto","year":"2021","unstructured":"Morimoto H, Kida S, Yoden E, et al. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol Ther. 2021;29(5):1853\u201361. https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.027.","journal-title":"Mol Ther"},{"key":"590_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","volume":"27","author":"T Okuyama","year":"2019","unstructured":"Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial. Mol Ther. 2019;27:456\u201364. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.005.","journal-title":"Mol Ther"},{"issue":"7","key":"590_CR22","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","volume":"29","author":"R Giugliani","year":"2021","unstructured":"Giugliani R, Martins AM, So S, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther. 2021;29(7):2378\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.019.","journal-title":"Mol Ther"},{"issue":"2","key":"590_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","volume":"29","author":"T Okuyama","year":"2021","unstructured":"Okuyama T, Eto Y, Sakai N, et al. A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol Ther. 2021;29(2):671\u20139. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.039.","journal-title":"Mol Ther"},{"key":"590_CR24","unstructured":"Denali Therapeutics. Denali Therapeutics announces new interim data from phase 1\/2 study of DNL310 (ETV:IDS) in MPS II (Hunter syndrome) at SSIEM 2022. News release. August 31, 2022. Available from: https:\/\/www.globenewswire.com\/news-release\/2022\/08\/31\/2507598\/0\/en\/Denali-Therapeutics-Announces-New-Interim-Data-from-Phase-1-2-Study-of-DNL310-ETV-IDS-in-MPS-II-Hunter-Syndrome-at-SSIEM-2022.html. Accessed 31 Aug 2022."},{"issue":"545","key":"590_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1163","volume":"12","author":"JC Ullman","year":"2020","unstructured":"Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood\u2013brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545): eaay1163. https:\/\/doi.org\/10.1126\/scitranslmed.aay1163.","journal-title":"Sci Transl Med."},{"issue":"19","key":"590_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145445","volume":"6","author":"A Arguello","year":"2021","unstructured":"Arguello A, Meisner R, Thomsen ER, et al. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome. JCI Insight. 2021;6(19): e145445. https:\/\/doi.org\/10.1172\/jci.insight.145445.","journal-title":"JCI Insight."},{"issue":"10","key":"590_CR27","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1021\/bc400319d","volume":"24","author":"RJ Boado","year":"2013","unstructured":"Boado RJ, Hui EKW, Lu JZ, Sumbria RK, Pardridge WM. Blood\u2013brain barrier molecular Trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24(10):1741\u20139. https:\/\/doi.org\/10.1021\/bc400319d.","journal-title":"Bioconjug Chem"},{"key":"590_CR28","unstructured":"ArmaGen Technologies. Pipeline-chart. Available from: http:\/\/armagen.com\/our-pipeline\/pipeline-chart. Accessed 10 Jan 2023."},{"issue":"1","key":"590_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","volume":"82","author":"GL Ellman","year":"1959","unstructured":"Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70\u20137. https:\/\/doi.org\/10.1016\/0003-9861(59)90090-6.","journal-title":"Arch Biochem Biophys"},{"key":"590_CR30","volume-title":"Proteins and proteomics: a laboratory manual","author":"RJ Simpson","year":"2003","unstructured":"Simpson RJ. Proteins and proteomics: a laboratory manual. Cold Spring Harbor: CSHL Press; 2003. (ISBN 0 87969 554)."},{"key":"590_CR31","unstructured":"Agilent. N-glycan preparation with InstantAB Kit user manual. Available from: https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/TDW-GP96NG-LB%20GlykoPrep%20Rapid%20N-Glycan%20Preparation%20with%20InstantAB%20090414AL.pdf. Accessed 1 Sep 2021."},{"issue":"6","key":"590_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1023\/a:1012763026526","volume":"24","author":"YV Voznyi","year":"2001","unstructured":"Voznyi YV, Keulemans JLM, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inhert Metab Dis. 2001;24(6):675\u201380. https:\/\/doi.org\/10.1023\/a:1012763026526.","journal-title":"J Inhert Metab Dis."},{"issue":"3","key":"590_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ymgme.2011.12.011","volume":"105","author":"AA Tolun","year":"2012","unstructured":"Tolun AA, Graham C, Shi Q, et al. A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots. Mol Genet Metab. 2012;105(3):519\u201321. https:\/\/doi.org\/10.1016\/j.ymgme.2011.12.011.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"590_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/jhg.2016.133","volume":"62","author":"C Kim","year":"2017","unstructured":"Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2):167\u201374. https:\/\/doi.org\/10.1038\/jhg.2016.133.","journal-title":"J Hum Genet"},{"issue":"4","key":"590_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10719-014-9523-0","volume":"31","author":"YK Chung","year":"2014","unstructured":"Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309\u201315. https:\/\/doi.org\/10.1007\/s10719-014-9523-0.","journal-title":"Glycoconj J"},{"issue":"22","key":"590_CR36","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.1073\/pnas.94.22.11963","volume":"94","author":"T Dierks","year":"1997","unstructured":"Dierks T, Schmidt B, von Figura K. Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. Proc Natl Acad Sci USA. 1997;94(22):11963\u20138. https:\/\/doi.org\/10.1073\/pnas.94.22.11963.","journal-title":"Proc Natl Acad Sci USA"},{"key":"590_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1042\/bj3260243","volume":"326","author":"G Millat","year":"1997","unstructured":"Millat G, Froissart R, Maire I, Bozon D. Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem J. 1997;326:243\u20137. https:\/\/doi.org\/10.1042\/bj3260243.","journal-title":"Biochem J"},{"issue":"3","key":"590_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","volume":"90","author":"J Muenzer","year":"2007","unstructured":"Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329\u201337. https:\/\/doi.org\/10.1016\/j.ymgme.2006.09.001.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"590_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/s0092-8674(03)00354-4","volume":"113","author":"JU Baenziger","year":"2003","unstructured":"Baenziger JU. A major step on the road to understanding a unique posttranslational modification and its role in a genetic disease. Cell. 2003;113(4):421\u20132. https:\/\/doi.org\/10.1016\/s0092-8674(03)00354-4.","journal-title":"Cell"},{"issue":"2","key":"590_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0304-4157(95)00004-b","volume":"1241","author":"A Hille-Rehfeld","year":"1995","unstructured":"Hille-Rehfeld A. Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. Biochim Biophys Acta. 1995;1241(2):177\u201394. https:\/\/doi.org\/10.1016\/0304-4157(95)00004-b.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"590_CR41","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/nbt1252","volume":"24","author":"G Walsh","year":"2006","unstructured":"Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24(10):1241\u201352. https:\/\/doi.org\/10.1038\/nbt1252.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"590_CR42","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/bit.25289","volume":"111","author":"RJ Boado","year":"2014","unstructured":"Boado RJ, Hui E-W, Lu JZ, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng. 2014;111(11):2317\u201325. https:\/\/doi.org\/10.1002\/bit.25289.","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"590_CR43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012;14(2):296\u2013302. https:\/\/doi.org\/10.1208\/s12248-012-9340-y.","journal-title":"AAPS J"},{"issue":"4","key":"590_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s0092-8674(03)00347-7","volume":"113","author":"T Dierks","year":"2003","unstructured":"Dierks T, Schmidt B, Borissenko LV, et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 2003;113(4):435\u201344. https:\/\/doi.org\/10.1016\/s0092-8674(03)00347-7.","journal-title":"Cell"},{"issue":"4","key":"590_CR45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s0092-8674(03)00348-9","volume":"113","author":"MP Cosma","year":"2003","unstructured":"Cosma MP, Pepe S, Annunziata I, et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003;113(4):445\u201356. https:\/\/doi.org\/10.1016\/s0092-8674(03)00348-9.","journal-title":"Cell"},{"issue":"6","key":"590_CR46","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/nprot.2012.045","volume":"7","author":"D Rabuka","year":"2012","unstructured":"Rabuka D, Rush JS, de Hart GW, Wu P, Bertozzi CR. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc. 2012;7(6):1052\u201367. https:\/\/doi.org\/10.1038\/nprot.2012.045.","journal-title":"Nat Protoc"},{"issue":"9","key":"590_CR47","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1073\/pnas.08078201","volume":"106","author":"P Wu","year":"2009","unstructured":"Wu P, Shui W, Carlson BL, Bertozzi CR. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc Natl Acad Sci USA. 2009;106(9):3000\u20135. https:\/\/doi.org\/10.1073\/pnas.08078201.","journal-title":"Proc Natl Acad Sci USA"},{"key":"590_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12896-016-0254-0","volume":"16","author":"D York","year":"2016","unstructured":"York D, Baker J, Holder PG, et al. Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper (II). BMC Biotechnol. 2016;16:23. https:\/\/doi.org\/10.1186\/s12896-016-0254-0.","journal-title":"BMC Biotechnol"},{"issue":"4","key":"590_CR49","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cell.2005.03.001","volume":"121","author":"T Dierks","year":"2005","unstructured":"Dierks T, Dickmanns A, Preusser-Kunze A, et al. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell. 2005;121(4):541\u201352. https:\/\/doi.org\/10.1016\/j.cell.2005.03.001.","journal-title":"Cell"},{"key":"590_CR50","unstructured":"European Medicines Agency. Elaprase: ERAP, scientific discussion. 2007. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/elaprase-epar-scientific-discussion_en.pdf. Accessed 7 Jul 2021."},{"issue":"3","key":"590_CR51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nrm1050","volume":"4","author":"P Ghosh","year":"2003","unstructured":"Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 2003;4(3):202\u201312. https:\/\/doi.org\/10.1038\/nrm1050.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"590_CR52","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1074\/jbc.M109.038836","volume":"285","author":"Y Kariya","year":"2010","unstructured":"Kariya Y, Kawamura C, Tabei T, Gu J. Bisecting GlcNAc residues on laminin-332 down-regulate galectin-3-dependent keratinocyte motility. J Biol Chem. 2010;285(5):3330\u201340. https:\/\/doi.org\/10.1074\/jbc.M109.038836.","journal-title":"J Biol Chem"},{"issue":"3","key":"590_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1073\/pnas.91.3.913","volume":"91","author":"C Hammond","year":"1994","unstructured":"Hammond C, Braakman I, Helenius A. Role of N-linked oligosaccharide ecognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc Natl Acad Sci USA. 1994;91(3):913\u20137. https:\/\/doi.org\/10.1073\/pnas.91.3.913.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"590_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0167-4838(82)90213-8","volume":"708","author":"IM Archer","year":"1982","unstructured":"Archer IM, Harper PS, Wusteman FS. Multiple forms of iduronate 2-sulphate sulphatase in human tissues and body fluids. Biochim Biophys Acta. 1982;708(2):134\u201340. https:\/\/doi.org\/10.1016\/0167-4838(82)90213-8.","journal-title":"Biochim Biophys Acta"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00590-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00590-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00590-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T21:39:12Z","timestamp":1684445952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00590-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00590-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"23 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by JSC \u201cGENERIUM\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of JSC \u201cGENERIUM\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal study-specific protocols were approved by the respective Institutional Animal Care and Use Committee. All procedures performed on live animals as part of this study by Covance Laboratories Limited (Harrogate, UK) are subject to the provisions of UK national law, in particular the Animals (Scientific Procedures) Act 1986. The study in mice was conducted by The Jackson Laboratories (Bar Harbor, USA) and complied with all applicable sections of the Guide for the Care and Use of Laboratory Animals from the National Research Council.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"VDG: conceptualization, supervision, methodology, validation, investigation, writing: original draft, writing: review and editing, visualization, formal analysis. MAS: supervision, methodology, formal analysis. IVL: supervision, methodology, validation, investigation, writing: original draft, formal analysis. MBD: methodology, investigation. EVR: investigation, methodology, writing: review and editing, formal analysis. AVR: methodology, investigation, visualization. MSP: methodology, investigation, visualization. RRS: project administration, conceptualization, resources, writing: review and editing. All authors contributed to the preparation of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}